Intech Investment Management LLC Makes New $834,000 Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Intech Investment Management LLC purchased a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 78,071 shares of the biopharmaceutical company’s stock, valued at approximately $834,000.

Other institutional investors have also recently made changes to their positions in the company. Xponance Inc. increased its position in Amicus Therapeutics by 5.3% in the 2nd quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 936 shares in the last quarter. Hazlett Burt & Watson Inc. grew its stake in Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 1,569 shares during the period. Arizona State Retirement System increased its holdings in shares of Amicus Therapeutics by 2.6% during the second quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock valued at $615,000 after acquiring an additional 1,577 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Amicus Therapeutics by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 1,884 shares during the period. Finally, OLD Second National Bank of Aurora bought a new position in shares of Amicus Therapeutics in the 3rd quarter worth $26,000.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total value of $79,500.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $9,398,532.40. This trade represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Over the last 90 days, insiders have sold 30,401 shares of company stock valued at $352,038. Company insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Cantor Fitzgerald upped their price objective on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Guggenheim lifted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. increased their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Jefferies Financial Group initiated coverage on Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 target price on the stock. Finally, StockNews.com raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 16th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.63.

Amicus Therapeutics Trading Up 0.9 %

NASDAQ FOLD opened at $9.96 on Friday. The stock has a market capitalization of $2.98 billion, a price-to-earnings ratio of -29.29 and a beta of 0.68. The business’s fifty day moving average is $10.75 and its 200-day moving average is $10.59. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.